Annual EBIT
-$33.75 M
-$8.38 M-33.00%
30 September 2022
Summary:
NeuBase Therapeutics annual earnings before interest & taxes is currently -$33.75 million, with the most recent change of -$8.38 million (-33.00%) on 30 September 2022. During the last 3 years, it has fallen by -$8.38 million (-33.00%).NBSE EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
-$1.82 M
+$1.63 M+47.16%
30 September 2023
Summary:
NeuBase Therapeutics quarterly earnings before interest & taxes is currently -$1.82 million, with the most recent change of +$1.63 million (+47.16%) on 30 September 2023.NBSE Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
-$13.73 M
+$5.81 M+29.73%
30 September 2023
Summary:
NeuBase Therapeutics TTM earnings before interest & taxes is currently -$13.73 million, with the most recent change of +$5.81 million (+29.73%) on 30 September 2023.NBSE TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NBSE EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | -33.0% | +76.4% | +52.7% |
| 5 y5 years | -29.8% | +59.6% | +53.6% |
NBSE EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | -364.3% | -114.3% | -160.6% |
NeuBase Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2023 | - | -$1.82 M(-47.2%) | -$13.73 M(-29.7%) |
| June 2023 | - | -$3.45 M(-15.8%) | -$19.53 M(-20.5%) |
| Mar 2023 | - | -$4.09 M(-6.3%) | -$24.58 M(-19.2%) |
| Dec 2022 | - | -$4.37 M(-42.8%) | -$30.41 M(-9.9%) |
| Sept 2022 | -$33.75 M(+33.0%) | -$7.63 M(-10.1%) | -$33.75 M(+1.5%) |
| June 2022 | - | -$8.49 M(-14.4%) | -$33.27 M(-0.5%) |
| Mar 2022 | - | -$9.92 M(+28.6%) | -$33.44 M(+15.2%) |
| Dec 2021 | - | -$7.71 M(+8.0%) | -$29.03 M(+14.4%) |
| Sept 2021 | -$25.38 M(+46.0%) | -$7.15 M(-17.5%) | -$25.38 M(+10.7%) |
| June 2021 | - | -$8.66 M(+57.0%) | -$22.93 M(+26.9%) |
| Mar 2021 | - | -$5.52 M(+36.0%) | -$18.07 M(+6.7%) |
| Dec 2020 | - | -$4.06 M(-13.6%) | -$16.93 M(-2.6%) |
| Sept 2020 | -$17.38 M(-33.2%) | -$4.70 M(+23.6%) | -$17.38 M(-51.0%) |
| June 2020 | - | -$3.80 M(-13.2%) | -$35.49 M(+8.1%) |
| Mar 2020 | - | -$4.38 M(-2.8%) | -$32.83 M(+10.9%) |
| Dec 2019 | - | -$4.50 M(-80.3%) | -$29.60 M(+13.8%) |
| Sept 2019 | -$26.00 M(+186.4%) | -$22.81 M(+1906.1%) | -$26.00 M(+511.3%) |
| June 2019 | - | -$1.14 M(-1.4%) | -$4.25 M(-0.7%) |
| Mar 2019 | - | -$1.15 M(+27.2%) | -$4.28 M(-6.3%) |
| Dec 2018 | - | -$906.40 K(-14.3%) | -$4.57 M(-41.7%) |
| Sept 2018 | -$9.08 M(-61.9%) | -$1.06 M(-9.3%) | -$7.85 M(-34.9%) |
| June 2018 | - | -$1.17 M(-19.2%) | -$12.05 M(-18.6%) |
| Mar 2018 | - | -$1.44 M(-65.5%) | -$14.81 M(-29.7%) |
| Dec 2017 | - | -$4.18 M(-20.5%) | -$21.06 M(-11.7%) |
| Sept 2017 | -$23.85 M(-5.8%) | -$5.26 M(+33.9%) | -$23.85 M(-6.1%) |
| June 2017 | - | -$3.93 M(-48.9%) | -$25.40 M(-12.6%) |
| Mar 2017 | - | -$7.69 M(+10.2%) | -$29.07 M(+1.3%) |
| Dec 2016 | - | -$6.98 M(+2.4%) | -$28.69 M(+13.4%) |
| Sept 2016 | -$25.31 M(+44.9%) | -$6.81 M(-10.4%) | -$25.31 M(+15.3%) |
| June 2016 | - | -$7.60 M(+4.0%) | -$21.96 M(+24.1%) |
| Mar 2016 | - | -$7.31 M(+103.4%) | -$17.69 M(+2.9%) |
| Dec 2015 | - | -$3.59 M(+3.9%) | -$17.19 M(-1.9%) |
| Sept 2015 | -$17.47 M(+91.5%) | -$3.46 M(+3.7%) | -$17.52 M(+2.2%) |
| June 2015 | - | -$3.33 M(-51.0%) | -$17.15 M(+8.1%) |
| Mar 2015 | - | -$6.81 M(+73.4%) | -$15.86 M(+43.9%) |
| Dec 2014 | - | -$3.92 M(+27.1%) | -$11.03 M(+20.9%) |
| Sept 2014 | -$9.12 M(+61.5%) | -$3.09 M(+50.8%) | -$9.12 M(+16.4%) |
| June 2014 | - | -$2.05 M(+4.0%) | -$7.84 M(+10.0%) |
| Mar 2014 | - | -$1.97 M(-2.6%) | -$7.13 M(+30.7%) |
| Dec 2013 | - | -$2.02 M(+12.2%) | -$5.45 M(-3.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2013 | -$5.65 M(+288.7%) | -$1.80 M(+35.0%) | -$5.65 M(+49.5%) |
| June 2013 | - | -$1.34 M(+356.9%) | -$3.78 M(+30.2%) |
| Mar 2013 | - | -$292.30 K(-86.8%) | -$2.90 M(-27.9%) |
| Dec 2012 | - | -$2.22 M(-3342.4%) | -$4.02 M(+176.8%) |
| Sept 2012 | -$1.45 M(-71.5%) | $68.40 K(-114.9%) | -$1.45 M(-49.5%) |
| June 2012 | - | -$459.80 K(-67.4%) | -$2.88 M(-48.2%) |
| Mar 2012 | - | -$1.41 M(-502.7%) | -$5.56 M(+29.2%) |
| Dec 2011 | - | $350.70 K(-125.8%) | -$4.30 M(-15.6%) |
| Sept 2011 | -$5.10 M(-1088.4%) | -$1.36 M(-56.7%) | -$5.10 M(+85.6%) |
| June 2011 | - | -$3.14 M(+1902.2%) | -$2.75 M(-1370.0%) |
| Mar 2011 | - | -$156.70 K(-64.9%) | $216.30 K(-2.6%) |
| Dec 2010 | - | -$446.60 K(-144.9%) | $222.00 K(-57.0%) |
| Sept 2010 | $515.90 K(-161.5%) | $993.70 K(-670.8%) | $515.80 K(-186.8%) |
| June 2010 | - | -$174.10 K(+15.3%) | -$594.20 K(-6.5%) |
| Mar 2010 | - | -$151.00 K(-1.2%) | -$635.40 K(-31.3%) |
| Dec 2009 | - | -$152.80 K(+31.4%) | -$924.80 K(+10.3%) |
| Sept 2009 | -$838.70 K(+28.3%) | -$116.30 K(-46.0%) | -$838.40 K(-17.9%) |
| June 2009 | - | -$215.30 K(-51.1%) | -$1.02 M(+24.5%) |
| Mar 2009 | - | -$440.40 K(+563.3%) | -$820.40 K(+72.4%) |
| Dec 2008 | - | -$66.40 K(-77.8%) | -$476.00 K(-27.1%) |
| Sept 2008 | -$653.60 K(<-9900.0%) | -$299.60 K(+2040.0%) | -$652.60 K(+84.9%) |
| June 2008 | - | -$14.00 K(-85.4%) | -$353.00 K(+4.1%) |
| Mar 2008 | - | -$96.00 K(-60.5%) | -$339.00 K(-81.9%) |
| Dec 2007 | - | -$243.00 K(<-9900.0%) | -$1.87 M(+15.0%) |
| Sept 2007 | $0.00(0.0%) | $0.00(0.0%) | -$1.63 M(0.0%) |
| June 2007 | - | $0.00(-100.0%) | -$1.63 M(+1.7%) |
| Mar 2007 | - | -$1.63 M(<-9900.0%) | -$1.60 M(-147.2%) |
| Dec 2006 | $0.00(-100.0%) | $0.00(0.0%) | $3.39 M(-78.9%) |
| Sept 2006 | - | $0.00(-100.0%) | $16.10 M(-17.2%) |
| June 2006 | - | $26.70 K(-99.2%) | $19.45 M(-14.2%) |
| Mar 2006 | - | $3.36 M(-73.5%) | $22.66 M(+2.0%) |
| Dec 2005 | $12.71 M(+35.7%) | $12.71 M(+279.0%) | $22.22 M(+83.9%) |
| Sept 2005 | - | $3.35 M(+3.6%) | $12.08 M(+9.4%) |
| June 2005 | - | $3.24 M(+10.5%) | $11.04 M(+9.0%) |
| Mar 2005 | - | $2.93 M(+14.1%) | $10.13 M(+8.2%) |
| Dec 2004 | $9.36 M(+45.4%) | $2.57 M(+11.0%) | $9.36 M(+37.8%) |
| Sept 2004 | - | $2.31 M(-0.4%) | $6.79 M(+51.6%) |
| June 2004 | - | $2.32 M(+7.4%) | $4.48 M(+107.4%) |
| Mar 2004 | - | $2.16 M | $2.16 M |
| Dec 2003 | $6.44 M | - | - |
FAQ
- What is NeuBase Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for NeuBase Therapeutics?
- What is NeuBase Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for NeuBase Therapeutics?
- What is NeuBase Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for NeuBase Therapeutics?
What is NeuBase Therapeutics annual earnings before interest & taxes?
The current annual EBIT of NBSE is -$33.75 M
What is the all time high annual EBIT for NeuBase Therapeutics?
NeuBase Therapeutics all-time high annual earnings before interest & taxes is $12.77 M
What is NeuBase Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of NBSE is -$1.82 M
What is the all time high quarterly EBIT for NeuBase Therapeutics?
NeuBase Therapeutics all-time high quarterly earnings before interest & taxes is $12.71 M
What is NeuBase Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of NBSE is -$13.73 M
What is the all time high TTM EBIT for NeuBase Therapeutics?
NeuBase Therapeutics all-time high TTM earnings before interest & taxes is $22.66 M